Deemesh Oudit
YOU?
Author Swipe
View article: Supplementary Table S4 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S4 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
40 Gene Miseq primers.
View article: Supplementary Table S1 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S1 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
ctDNA patient list.
View article: Supplementary Methods from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Methods from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
Supplementary Methods
View article: Supplementary Table S5 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S5 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
CDXs list.
View article: Data from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Data from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
Targeted therapies and immunotherapies have transformed melanoma care, extending median survival from ∼9 to over 25 months, but nevertheless most patients still die of their disease. The aim of precision medicine is to tailor care for indi…
View article: Supplementary Figure S1 - S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Figure S1 - S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
Supplementary Figure S1. IGV visualization for whole exome sequencing of codon Q61 of NRAS in the pre-treatment tumor vs. the relapsed tumor in patient 1. The red color indicates the A>G for the p.Q61R mutation in the tumor. Supplementary …
View article: Supplementary Table S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
PDXs and WES list.
View article: Data from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Data from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
Targeted therapies and immunotherapies have transformed melanoma care, extending median survival from ∼9 to over 25 months, but nevertheless most patients still die of their disease. The aim of precision medicine is to tailor care for indi…
View article: Supplementary Table S2 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S2 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
10 gene Miseq primers.
View article: Supplementary Table S1 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S1 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
ctDNA patient list.
View article: Supplementary Methods from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Methods from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
Supplementary Methods
View article: Supplementary Figure S1 - S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Figure S1 - S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
Supplementary Figure S1. IGV visualization for whole exome sequencing of codon Q61 of NRAS in the pre-treatment tumor vs. the relapsed tumor in patient 1. The red color indicates the A>G for the p.Q61R mutation in the tumor. Supplementary …
View article: Supplementary Table S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S3 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
PDXs and WES list.
View article: Supplementary Table S5 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S5 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
CDXs list.
View article: Supplementary Table S2 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S2 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
10 gene Miseq primers.
View article: Supplementary Table S4 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
Supplementary Table S4 from Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Open
40 Gene Miseq primers.
View article: Supplementary Tables from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Supplementary Tables from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma Open
Supplementary Tables 1-6
View article: Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma Open
Purpose:Cancer susceptibility and mortality are higher in males, and the mutational and transcriptomic landscape of cancer differs by sex. The current assumption is that men are at higher risk of epithelial cancers as they expose more to c…
View article: Supplementary Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Supplementary Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma Open
SF1, SF2 Supp Methods Supp Table Legends
View article: Supplementary Tables from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Supplementary Tables from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma Open
Supplementary Tables 1-6
View article: Supplementary Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Supplementary Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma Open
SF1, SF2 Supp Methods Supp Table Legends
View article: Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Data from Female Immunity Protects from Cutaneous Squamous Cell Carcinoma Open
Purpose:Cancer susceptibility and mortality are higher in males, and the mutational and transcriptomic landscape of cancer differs by sex. The current assumption is that men are at higher risk of epithelial cancers as they expose more to c…
View article: Hypothesised cutaneous sites of origin of stage <scp>III</scp> melanomas with unknown primary: A multicentre study
Hypothesised cutaneous sites of origin of stage <span>III</span> melanomas with unknown primary: A multicentre study Open
Based on molecular evidence that melanomas with unknown primary (MUPs) arise from the skin, we hypothesised that sites of MUPs are disproportionately on trunk and lower limbs, sites that are not readily visible to patients and clinicians. …
View article: Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Female Immunity Protects from Cutaneous Squamous Cell Carcinoma Open
Purpose: Cancer susceptibility and mortality are higher in males, and the mutational and transcriptomic landscape of cancer differs by sex. The current assumption is that men are at higher risk of epithelial cancers as they expose more to …
View article: Reconstruction of the Tragus Using a Pedicled Chondrocutaneous Superficial Temporal Artery Perforator Flap
Reconstruction of the Tragus Using a Pedicled Chondrocutaneous Superficial Temporal Artery Perforator Flap Open
We present an interesting and novel technique to reconstruct the tragus of the ear after oncological resection, using a pedicled chondrocutaneous superficial temporal artery perforator (STAP) flap.
View article: Female immunity protects from cutaneous squamous cell carcinoma
Female immunity protects from cutaneous squamous cell carcinoma Open
Purpose Cancer susceptibility and mortality are higher in males, and the mutational and transcriptomic landscape of cancer differs by sex. The current assumption is that men are at higher risk of epithelial cancers as they expose more to c…
View article: Is skipped nodal metastasis a phenomenon of cutaneous melanoma?
Is skipped nodal metastasis a phenomenon of cutaneous melanoma? Open
Occurrence of SNM in cutaneous melanoma is highly unlikely.
View article: Letter to the Editor in Response to “Eliminating Preoperative Lymphoscintigraphy in Extremity Melanomas”
Letter to the Editor in Response to “Eliminating Preoperative Lymphoscintigraphy in Extremity Melanomas” Open
Sir, We read with great interest the paper by the authors from the Plastic and Reconstructive Surgery Section of the Yale University School of Medicine on the possibility of eliminating preoperative lymphoscintigraphy (POLSG) in extremity …
View article: Reconstruction of a Large Full-Thickness Alar Defect Using an Extended Free Composite Flap from the Pinna: A Case Report
Reconstruction of a Large Full-Thickness Alar Defect Using an Extended Free Composite Flap from the Pinna: A Case Report Open
Alar reconstruction can pose a challenging task in reconstructive surgery. Herein, we describe a case of a large full-thickness alar defect (involving the full- thickness of the left ala, 50% of the tip of the nose and extending over the l…